Paclitaxel DCB
Paclitaxel DCB 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Peripheral Vascular Disease、Peripheral Arterial Disease。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
2 项
已进入 III/IV 期
16 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Cook Research Incorporated
- Seoul National University Hospital
- Peking Union Medical College Hospital
- Xijing Hospital
- Medtronic Vascular
- Genoss Co., Ltd.
- Guangdong Provincial People's Hospital
- Orchestra BioMed, Inc
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
South Korea、中国、美国、加拿大、德国、中国香港、爱尔兰、日本、Singapore、英国、比利时、Poland
正在招募患者的 Paclitaxel DCB 研究
Safety and Efficacy of Paclitaxel Coated PTCA Balloon Catheter With a Shellac Plus Vitamin E Excipient (GENOSS® DCB) in Patients With Coronary In-stent Restenosis (ISR): A Prospective, Multi-center, Observational Study
不适用招募中South KoreaNCT06104007DCB Versus Primary Selective Stenting in TASC C/D Femoropopliteal Artery Disease
不适用招募中中国NCT05517291A Single-Center, Retrospective, Propensity-Score-Matched Cohort Study Comparing Drug-Coated Balloon Versus Drug-Eluting Stent for Reducing Immediate Post-Procedural Slow-Flow/No-Reflow in Acute ST-Elevation Myocardial Infarction Patients With High Thrombus Burden
不适用招募中中国NCT07806370Prevail Global Study
不适用招募中美国加拿大德国中国香港NCT06535854Safety and Effectiveness of GENOSS PCB in Patients With Long Femoropopliteal Lesion
不适用招募中South KoreaNCT07425171D-BACE in Combination With Chemotherapy and Camrelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
II 期招募中中国NCT07016126Virtue® SAB in the Treatment of Coronary ISR Trial
不适用招募中美国NCT07045194A Single Arm Trial to Evaluate the Safety and Efficacy of the Long (> 150mm) PasseoTM-18 LuxTM Drug-coated Balloon in the Treatment of Subjects With Infrainguinal Stenotic, Restenotic or Occlusive Lesions
不适用招募中比利时NCT07385573Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus
III 期招募中美国NCT05561114Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel
III 期招募中美国NCT05561127STAR-PAK Study: Evaluating the Safety and Efficacy of PAK® (Paclitaxel Coated Balloon) in Treating Atherosclerotic Femoro-Popliteal Lesions
不适用招募中Poland西班牙NCT06734221Clinical Outcomes of Drug-Coated Balloons in the Treatment of Patients With Coronary De Novo Chronic Total Occlusion Lesions
不适用招募中中国NCT07463664Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)
不适用招募中意大利NCT06535568Clinical Impact of DCB-based Versus DES-based Intervention in Patients With MVCAD
不适用招募中South KoreaNCT07539324SPAGO: Sirolimus Paclitaxel Angiographic Gain Objective
不适用招募中意大利NCT06373601Paclitaxel-Coated Pulmonary Balloon for the Treatment of Benign Central Airway Stenosis
不适用招募中美国NCT07191860EVERO Drug-coated Balloon (DCB) Randomized Trial
不适用招募中美国NCT07144150Acotec DCB Post Market Clinical Follow-up
不适用招募中德国NCT04393389Drug-Eluting Balloon Treatment vs. Guideline-Directed Medical Therapy for the Treatment of Lipid-Rich Plaques
不适用招募中荷兰NCT07107971Evaluation of the Optilume BPH Catheter System and the Rezum Water Vapor Therapy in Treating Benign Prostatic Hyperplasia
不适用招募中加拿大NCT06769997Drug-Coated Balloon in Native Chronic Total Occlusion Percutaneous Coronary Intervention
不适用招募中PolandNCT06275386Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study
不适用招募中美国NCT06312722Stents Versus PAclitaxel Coated Balloons for Revascularization of CompleX and Small Coronary Vessels (SPARX) Trial
不适用招募中瑞士NCT07397845Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis
不适用招募中美国NCT07290140
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。